Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Director | June 29, 2026 | July 01, 2026 |
| Pelthos Therapeutics Inc.PTHS · Entity 6798 | Director | October 02, 2026 | October 06, 2026 |
| Savara IncSVRA · Entity 4900 | Director · CHIEF EXECUTIVE OFFICER | December 14, 2025 | December 16, 2025 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Director · President & CEO | February 20, 2019 | February 22, 2019 |
| Zyla Life SciencesZCOR · Entity 148990 | Director | May 20, 2020 | May 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $154.84 · Expires 2036-06-29 | Direct | 6,000 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 6,000 · Balance 6,000 F1: The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
Pelthos Therapeutics Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,578 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 786 · Balance 13,578 F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
Savara Inc
Report date December 14, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,188,050 |
Ending reported balance
After 2025-12-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-14 · Tax withholding · Disposed 195,705 · Balance 1,317,045 F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Row 2 · 2025-12-16 · Gift · Disposed 128,995 · Balance 1,188,050 F2: On December 16, 2025, the reporting person transferred 128,995 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the reporting person disclaims beneficial ownership of the shares held by the trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units.
F2: On December 16, 2025, the reporting person transferred 128,995 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the reporting person disclaims beneficial ownership of the shares held by the trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any.
Strongbridge Biopharma plc
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 72,608 |
Reported balance
After 2019-02-20 transaction · row 1
1 source rowRow 1 · 2019-02-20 · Grant · Acquired 50,000 · Balance 72,608 F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2029-02-20 | Direct | 400,000 |
Reported balance
After 2019-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-20 · Grant · Acquired 400,000 · Balance 400,000 F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.
Zyla Life Sciences
Report date May 20, 2020 · Filed May 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Disposition to issuer · Disposed 26,953 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 10,491 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 · Expires 2033-08-15 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 9,063 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2020 Filed Dec 17, 2020 17:34 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-20-063981 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 16, 2020, subject to the reporting person's continued service with the Issuer. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 01:45 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 898,639 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000899243-20-025225 · doc4.xml · derivative · entry 4 Pauls Matthew · CIK 0001573429 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,639 Underlying: Common Stock · 898,639 shares Expires 2030-09-15 F5 · derivative.exercise_date: The shares subject to the option vest and become exercisable in thirty-six equal installments on each monthly anniversary of September 11, 2020, subject to the reporting person's continued service with the Issuer. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 01:45 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 227,272 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025225 · doc4.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,922 F2 · shares: Represents RSUs that vest in full on the earlier to occur of (i) December 31, 2021 or (ii) the hiring of a permanent Chief Executive Officer of the Issuer, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:31 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Disposition to issuerCommon Stock | 26,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-064791 · a4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · kind: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. F1 · price: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · price: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:12 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005105 · edgar.xml · derivative · entry 3 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:12 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Tax withholdingCommon Stock | 952 | $1.75 | $1,666.00 |
DisclosureSEC source: 0001179110-20-005105 · edgar.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,715 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 22:12 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 6,667 | $1.75 | $11,667.25 |
DisclosureSEC source: 0001179110-20-005105 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 23:39 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005215 · edgar.xml · derivative · entry 3 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 23:39 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Tax withholdingCommon Stock | 1,805 | $1.75 | $3,158.75 |
DisclosureSEC source: 0001179110-20-005215 · edgar.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,862 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 23:39 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 6,667 | $1.75 | $11,667.25 |
DisclosureSEC source: 0001179110-20-005215 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 01:41 UTC | Zyla Life Sciences ZCOR · Entity 148990 | GrantCommon Stock | 13,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003202 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,620 F1 · shares: Represents restricted stock units, which vest the day prior to the Company's annual meeting of stockholders to be held in 2021. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 23:03 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0000899243-19-030072 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in twelve equal installments on each quarterly anniversary of December 20, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 00:53 UTC | Zyla Life Sciences ZCOR · Entity 148990 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005161 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 13:50 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001179110-19-002283 · edgar.xml · derivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-02-20 F2 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 13:50 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002283 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,608 F1 · shares: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:38 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0000899243-18-031096 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in twelve equal installments on each quarterly anniversary of December 13, 2018, subject to the reporting person's continued service with the Issuer. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 19:37 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | Tax withholdingOrdinary Shares | 17,392 | $6.60 | $114,787.20 |
DisclosureSEC source: 0001179110-18-003030 · edgar.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,608 F1 · shares: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:59 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001179110-18-001638 · edgar.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-02-05 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning May 5, 2018, provided employee is employed by the Company on each vesting date. Read SEC document |
| May 25, 2017 Filed May 26, 2017 22:45 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0000899243-17-014620 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-05-25 F1 · derivative.exercise_date: The option vests and becomes exercisable in six equal monthly installments on each monthly anniversary of May 25, 2017, subject to the reporting person's continued service with the Issuer. Read SEC document |
| April 27, 2017 Filed Sep 16, 2020 01:45 UTC | Savara Inc SVRA · Entity 4900 | Exercise / conversionRestricted Stock Units · Derivative | 650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025225 · doc4.xml · derivative · entry 3 Pauls Matthew · CIK 0001573429 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The vesting of the restricted stock units ("RSUs") occurred upon April 27, 2017 upon the consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among Mast Therapeutics, Inc., Savara Inc., and Victoria Merger Corp. (the "Merger Agreement") but due to an administrative error was not reported at that time, and the shares were omitted from subsequent Form 4 filings. F3 · shares: Each RSU represents a contingent right to receive one share of the issuer's common stock. The amount reported reflects the 70-for-one reverse stock split implemented by the issuer on April 27, 2017. F4 · derivative.exercise_date: The restricted stock units vested in full on April 27, 2017, upon consummation of the merger transaction contemplated by the Merger Agreement. F4 · derivative.expiration_date: The restricted stock units vested in full on April 27, 2017, upon consummation of the merger transaction contemplated by the Merger Agreement. Read SEC document |
| April 27, 2017 Filed Sep 16, 2020 01:45 UTC | Savara Inc SVRA · Entity 4900 | Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025225 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The vesting of the restricted stock units ("RSUs") occurred upon April 27, 2017 upon the consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among Mast Therapeutics, Inc., Savara Inc., and Victoria Merger Corp. (the "Merger Agreement") but due to an administrative error was not reported at that time, and the shares were omitted from subsequent Form 4 filings. Read SEC document |
| January 23, 2017 Filed Jan 23, 2017 22:16 UTC | Savara Inc MSTX · Entity 4900 | GrantRestricted Stock Units · Derivative | 45,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005127 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,535 Underlying: Common Stock · 45,535 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). F2 · derivative.expiration_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.